NasdaqCM - Delayed Quote • USD
Senti Biosciences, Inc. (SNTI)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 5:31 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.42 | -0.42 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | -- | 1 | 2 |
| Avg. Estimate | -- | -- | 2.56M | 8.9M |
| Low Estimate | 300k | -- | 3.46M | 3.8M |
| High Estimate | 300k | -- | 3.46M | 14M |
| Year Ago Sales | 59k | -- | 4.29M | 2.56M |
| Sales Growth (year/est) | -- | -- | -40.20% | 247.50% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.44 | -0.43 | -0.48 | -0.44 |
| EPS Actual | -0.42 | -0.42 | -0.42 | 0.24 |
| Difference | 0.02 | 0.01 | 0.06 | 0.68 |
| Surprise % | 4.50% | 2.30% | 12.50% | 154.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.23 | 0 | -1.34 | -0.75 |
| 30 Days Ago | -0.23 | 0 | -1.34 | -0.75 |
| 60 Days Ago | -0.23 | 0 | -1.34 | -0.75 |
| 90 Days Ago | -0.23 | 0 | -1.34 | -0.75 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SNTI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.50% |
| Next Qtr. | -- | -- | -- | 11.40% |
| Current Year | -- | -- | -- | 5.20% |
| Next Year | -- | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Chardan Capital: Buy to Buy | 8/15/2023 |
| Maintains | Chardan Capital: Buy to Buy | 5/11/2023 |
| Maintains | Morgan Stanley: Equal-Weight | 3/24/2023 |
| Maintains | Chardan Capital: Buy | 3/23/2023 |
| Maintains | Chardan Capital: Buy | 1/30/2023 |
| Maintains | Morgan Stanley: Equal-Weight | 1/27/2023 |
Related Tickers
VRAX Virax Biolabs Group Limited
0.6636
+0.85%
QNRX Quoin Pharmaceuticals, Ltd.
0.6321
-5.30%
XCUR Exicure, Inc.
0.5150
-4.68%
SXTP 60 Degrees Pharmaceuticals, Inc.
0.2423
-3.31%
KTTA Pasithea Therapeutics Corp.
6.95
-0.71%
QUIA.ST QuiaPEG Pharmaceuticals Holding AB (publ)
0.0753
+3.15%
RNAZ TransCode Therapeutics, Inc.
0.4399
-4.35%
KPRX Kiora Pharmaceuticals, Inc.
0.5058
-12.72%
VRPX Virpax Pharmaceuticals, Inc.
3.1700
+0.63%
INAB IN8bio, Inc.
1.0600
+1.92%